Nan Fang Du Shi Bao·2025-06-05 12:14Core Viewpoint - The controversy surrounding the collagen content in the product from Giant Bio (02367.HK) continues despite the release of test results, which confirmed the presence of recombinant collagen protein in their product, but raised further questions about the testing methods used [1][4][6]. Group 1: Test Results and Controversy - Giant Bio announced that their product, the Human-like Recombinant Collagen Essence, contains recombinant collagen protein with a content greater than 0.1% [1][4]. - The testing involved multiple methods, including LC-MS/MS for qualitative analysis and the Biuret method for quantitative analysis, but the choice of methods has been criticized for lacking consistency [5][6]. - The release of the test results led to a significant drop in Giant Bio's market value, with a loss exceeding 60 billion HKD in a single day [4][7]. Group 2: Market Competition - The ongoing dispute over collagen and hyaluronic acid is viewed as a commercial battle between Giant Bio and Huaxi Biological, both competing for market share in the beauty and skincare sector [2][10]. - Huaxi Biological has publicly criticized Giant Bio, suggesting that the latter has been using aggressive marketing tactics without scientific backing [10]. - The market dynamics are further complicated by the upcoming peak sales season, with both companies vying for consumer attention [2][10]. Group 3: Industry Standards - The controversy highlights the lack of unified testing standards in the recombinant collagen industry, leading to significant discrepancies in test results from different institutions [6]. - The National Medical Products Administration is set to establish industry standards for the detection of recombinant collagen in cosmetics by 2025 [6].